The closing price of Acadia Pharmaceuticals Inc (NASDAQ: ACAD) was $19.98 for the day, down -17.20% from the previous closing price of $24.13. In other words, the price has decreased by -$4.15 from its previous closing price. On the day, 7401502 shares were traded. ACAD stock price reached its highest trading level at $20.48 during the session, while it also had its lowest trading level at $19.11.
Ratios:
Our analysis of ACAD’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.50 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 197.72. For the most recent quarter (mrq), Quick Ratio is recorded 2.28 and its Current Ratio is at 2.42. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 12, 2024, Reiterated its Buy rating but revised its target price to $32 from $36 previously.
On March 12, 2024, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $39 to $25.
On January 30, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $40.Robert W. Baird initiated its Outperform rating on January 30, 2024, with a $40 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 26 ’24 when DAVIS STEPHEN sold 5,577 shares for $24.67 per share. The transaction valued at 137,585 led to the insider holds 101,890 shares of the business.
Schneyer Mark C. sold 772 shares of ACAD for $19,045 on Feb 26 ’24. The EVP, CHIEF FINANCIAL OFFICER now owns 21,067 shares after completing the transaction at $24.67 per share. On Feb 26 ’24, another insider, Teehan Brendan, who serves as the EVP, COO, HEAD OF COMMERCIAL of the company, sold 624 shares for $24.67 each. As a result, the insider received 15,394 and left with 31,432 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 3.29B and an Enterprise Value of 2.91B. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.53 while its Price-to-Book (P/B) ratio in mrq is 7.62. Its current Enterprise Value per Revenue stands at 4.01 whereas that against EBITDA is -42.91.
Stock Price History:
Over the past 52 weeks, ACAD has reached a high of $33.99, while it has fallen to a 52-week low of $17.71. The 50-Day Moving Average of the stock is 26.42, while the 200-Day Moving Average is calculated to be 25.56.
Shares Statistics:
ACAD traded an average of 1.97M shares per day over the past three months and 2.81M shares per day over the past ten days. A total of 164.65M shares are outstanding, with a floating share count of 163.51M. Insiders hold about 0.76% of the company’s shares, while institutions hold 97.15% stake in the company. Shares short for ACAD as of Feb 29, 2024 were 10.81M with a Short Ratio of 5.47, compared to 7.68M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.56% and a Short% of Float of 8.76%.
Earnings Estimates
The firm’s stock currently is rated by 19 analysts. On average, analysts expect EPS of $0.06 for the current quarter, with a high estimate of $0.24 and a low estimate of -$0.08, while EPS last year was -$0.27. The consensus estimate for the next quarter is $0.2, with high estimates of $0.27 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.95 and $0.3 for the fiscal current year, implying an average EPS of $0.64. EPS for the following year is $1.39, with 21 analysts recommending between $2.49 and $0.79.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 19 analysts. It ranges from a high estimate of $235.9M to a low estimate of $201.3M. As of the current estimate, Acadia Pharmaceuticals Inc’s year-ago sales were $118.46M, an estimated increase of 76.40% from the year-ago figure. For the next quarter, 19 analysts are estimating revenue of $242.02M, an increase of 53.40% less than the figure of $76.40% in the same quarter last year. There is a high estimate of $253M for the next quarter, whereas the lowest estimate is $235.9M.
A total of 21 analysts have provided revenue estimates for ACAD’s current fiscal year. The highest revenue estimate was $989.5M, while the lowest revenue estimate was $939M, resulting in an average revenue estimate of $966.41M. In the same quarter a year ago, actual revenue was $726.44M, up 33.00% from the average estimate. Based on 21 analysts’ estimates, the company’s revenue will be $1.14B in the next fiscal year. The high estimate is $1.31B and the low estimate is $993.2M. The average revenue growth estimate for next year is up 17.60% from the average revenue estimate for this year.
